360 related articles for article (PubMed ID: 34714687)
1. Lack of CD8
Horton BL; Morgan DM; Momin N; Zagorulya M; Torres-Mejia E; Bhandarkar V; Wittrup KD; Love JC; Spranger S
Sci Immunol; 2021 Oct; 6(64):eabi8800. PubMed ID: 34714687
[TBL] [Abstract][Full Text] [Related]
2. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
3. CD28/PD1 co-expression: dual impact on CD8
Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
[TBL] [Abstract][Full Text] [Related]
4. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
5. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade-unresponsive human tumor-infiltrating CD8
Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC
Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901
[TBL] [Abstract][Full Text] [Related]
7. NFATc1 Promotes Antitumoral Effector Functions and Memory CD8
Heim L; Friedrich J; Engelhardt M; Trufa DI; Geppert CI; Rieker RJ; Sirbu H; Finotto S
Cancer Res; 2018 Jul; 78(13):3619-3633. PubMed ID: 29691251
[TBL] [Abstract][Full Text] [Related]
8. CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer.
Wu P; Zhao L; Chen Y; Xin Z; Lin M; Hao Z; Chen X; Chen D; Wu D; Chai Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3603-3616. PubMed ID: 33934206
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
10. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
11. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
12. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Caushi JX; Zhang J; Ji Z; Vaghasia A; Zhang B; Hsiue EH; Mog BJ; Hou W; Justesen S; Blosser R; Tam A; Anagnostou V; Cottrell TR; Guo H; Chan HY; Singh D; Thapa S; Dykema AG; Burman P; Choudhury B; Aparicio L; Cheung LS; Lanis M; Belcaid Z; El Asmar M; Illei PB; Wang R; Meyers J; Schuebel K; Gupta A; Skaist A; Wheelan S; Naidoo J; Marrone KA; Brock M; Ha J; Bush EL; Park BJ; Bott M; Jones DR; Reuss JE; Velculescu VE; Chaft JE; Kinzler KW; Zhou S; Vogelstein B; Taube JM; Hellmann MD; Brahmer JR; Merghoub T; Forde PM; Yegnasubramanian S; Ji H; Pardoll DM; Smith KN
Nature; 2021 Aug; 596(7870):126-132. PubMed ID: 34290408
[TBL] [Abstract][Full Text] [Related]
14. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
[TBL] [Abstract][Full Text] [Related]
15. CD103
Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
[TBL] [Abstract][Full Text] [Related]
16. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F; Bomze D; Lichtensteiger C; Walter V; Niederer R; Hasan Ali O; Wyss N; Bauer J; Freudenmann LK; Marcu A; Wolfschmitt EM; Haen S; Gross T; Abdou MT; Diem S; Knöpfli S; Sinnberg T; Hofmeister K; Cheng HW; Toma M; Klümper N; Purde MT; Pop OT; Jochum AK; Pascolo S; Joerger M; Früh M; Jochum W; Rammensee HG; Läubli H; Hölzel M; Neefjes J; Walz J; Flatz L
Sci Immunol; 2022 Sep; 7(75):eabn9644. PubMed ID: 36054337
[TBL] [Abstract][Full Text] [Related]
17. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
[TBL] [Abstract][Full Text] [Related]
18. The ectonucleotidase CD39 identifies tumor-reactive CD8
Chow A; Uddin FZ; Liu M; Dobrin A; Nabet BY; Mangarin L; Lavin Y; Rizvi H; Tischfield SE; Quintanal-Villalonga A; Chan JM; Shah N; Allaj V; Manoj P; Mattar M; Meneses M; Landau R; Ward M; Kulick A; Kwong C; Wierzbicki M; Yavner J; Egger J; Chavan SS; Farillas A; Holland A; Sridhar H; Ciampricotti M; Hirschhorn D; Guan X; Richards AL; Heller G; Mansilla-Soto J; Sadelain M; Klebanoff CA; Hellmann MD; Sen T; de Stanchina E; Wolchok JD; Merghoub T; Rudin CM
Immunity; 2023 Jan; 56(1):93-106.e6. PubMed ID: 36574773
[TBL] [Abstract][Full Text] [Related]
19. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer.
Zhang Y; Huang S; Gong D; Qin Y; Shen Q
Cell Mol Immunol; 2010 Sep; 7(5):389-95. PubMed ID: 20514052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
